Indaptus enters $100M ATM offering agreement with H.C. Wainwright

Indaptus Therapeutics, Inc.

Amended and restated ATM agreement dated Aug 28, 2026, replacing June 2022 agreement with H.C. Wainwright.
Company may sell up to $100M of common stock through Wainwright as sales agent or principal.
Placement fee of 3.0% of gross sales price for agent sales; no obligation to sell any shares.
Prospectus supplement filed Aug 31, 2026 under existing Form S-3 shelf registration (File No. 333-289573).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.